New Indication: Trelegy Ellipta
Trelegy Ellipta is now approved for the maintenance treatment of asthma in patients aged 18 years and older. Learn more about this new indication with our slideshow, complete drug monograph, and downloadable PDF.
Trelegy Ellipta is now approved for the maintenance treatment of asthma in patients aged 18 years and older. Learn more about this new indication with our slideshow, complete drug monograph, and downloadable PDF.
Patients with asthma and/or chronic obstructive pulmonary disease have an increased risk for the development of long-term lower back pain.
In addition to their analgesic effects, opioid binding to opioid receptors leads to the release of histamine from mast cells, including those implicated in asthma and allergic rhinitis.
Children with persistent asthma are at increased risk for migraine, and treatment with anti-asthma or anti-allergy medication may lower this risk.
Odds of herpes zoster 70% higher among people with respiratory condition.
Researchers suggest asthma is stronger predictor of chronic migraines than depression.